A placebo-controlled, double-blind, randomized, two-center, pilot trial of Cop 1 in chronic progressive multiple sclerosis

Neurology

Volumn 41, Issue 4, 1991, Pages 533-539

  Bornstein, M B ^a   Miller, A ^d   Slagle, S ^a   Weitzman, M ^a   Drexler, E ^d   Keilson, M ^d   Spada, V ^a   Weiss, W ^a   Appel, S ^b   Rolak, L ^b   Harati, Y ^b   Brown, S ^b   Arnon, R ^c   Jacobsohn, I ^c   Teitelbaum, D ^c   Sela, M ^c  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^d MAIMONIDES MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CORTICOTROPIN; GLATIRAMER; PLACEBO; POLYMER; POLYPEPTIDE;

ADULT; ANXIETY; CONFERENCE PAPER; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FLUSHING; HEART PALPITATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; SIDE EFFECT; SUBCUTANEOUS DRUG ADMINISTRATION;

CHRONIC DISEASE; DISABILITY EVALUATION; DOUBLE-BLIND METHOD; HUMAN; MULTIPLE SCLEROSIS; NEUROLOGIC EXAMINATION; PEPTIDES; PILOT PROJECTS; PLACEBOS; STEROIDS; SUPPORT, U.S. GOV'T, P.H.S.; TIME FACTORS; WALKING;

EID: 0025817469     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/wnl.41.4.533     Document Type: Article

References (15)

1. Teitelbaum D, Meshorer A, Hirshfeld T, Arnon R, Sela M. Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide. Eur J Immunol 1971;1:242-248.
2. Webb C, Teitelbaum D, Arnon R, Sela M. In vivo and in vitro immunological cross-reactions between basic encephalitogen and synthetic basic polypeptides capable of suppressing experimental allergic encephalomyelitis. Eur J Immunol 1973;3:279-286.
3. Webb C, Teitelbaum D, Herz A, Arnon R, Sela M. Molecular requirements involved in suppression of EAE by synthetic basic copolymers of amino acids. Immunochemistry 1976;13:333-337.
4. Teitelbaum D, Webb C, Meshorer A, Arnon R, Sela M. Suppression by synthetic polypeptides of experimental allergic encephalomyelitis induced in guinea pigs and rabbits with bovine and human basic encephalitogen. Eur J Immunol 1973;3:273-279.
5. Lando Z, Teitelbaum T, Arnon R. Effect of cyclophosphamide on suppressor cell activity in mice unresponsive to EAE. J Immunol 1979;123:2156-2160.
6. Teitelbaum D, Webb C, Bree M, Meshorer A, Arnon R, Sela M. Suppression of experimental allergic encephalomyelitis in rhesus monkeys by a synthetic basic copolymer. Clin Immunol Immuno- pathol 1974;3:256-262.
7. Keith AB, Arnon R, Teitelbaum D, Caspary EA, Wisniewski HM. The effect of Cop 1, a synthetic polypeptide, on chronic relapsing experimental allergic encephalomyelitis in guinea pigs. J Neurol Sci 1979;42:267-274.
8. Arnon R. Experimental allergic encephalomyelitis—susceptibility and suppression. Immunol Rev 1981;55:5-30.
9. Abramsky O, Teitelbaum D, Arnon R. Effect of a synthetic polypeptide (Cop 1) on patients with multiple sclerosis and acute disseminated encephalomyelitis: preliminary report. J Neurol Sci 1977;31:433-438.
10. Bornstein MB, Miller A, Teitelbaum D, Arnon R, Sela M. Multiple sclerosis: trial of a synthetic polypeptide. Ann Neurol 1982;11:317-319.
11. Bornstein MB, Miller A, Slagle S, et al. A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis. N Engl J Med 1987;317:408-414.
12. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-231.
13. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-1452.
14. Hauser L, Dawson DM, Lehrich JR, et al. Intense immunosuppression in progressive multiple sclerosis. N Engl J Med 1983;308:173-180.
15. Anderson S, Auguier A, Hauck W, et al. Statistical methods for comparative studies. Somerset, NJ: John Wiley & Sons, 1980:199-214.